Metformin—an adjunct antineoplastic therapy—divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET …
P Habibollahi, NS Van Den Berg… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Over the last several years, epidemiologic data have suggested that the antidiabetes drug
metformin (MET), an adenosine monophosphate–activated protein kinase (AMPK) activator …
metformin (MET), an adenosine monophosphate–activated protein kinase (AMPK) activator …
[HTML][HTML] Effects of metformin on tumor hypoxia and radiotherapy efficacy: a [18F]HX4 PET imaging study in colorectal cancer xenografts
S De Bruycker, C Vangestel, S Staelens, L Wyffels… - EJNMMI research, 2019 - Springer
Background In a colorectal cancer xenograft model, we investigated the therapeutic effect of
metformin on tumor hypoxia with [18 F] flortanidazole ([18 F] HX4) small-animal positron …
metformin on tumor hypoxia with [18 F] flortanidazole ([18 F] HX4) small-animal positron …
Metformin temporal and localized effects on gut glucose metabolism assessed using 18F-FDG PET in mice
M Massollo, C Marini, M Brignone… - Journal of Nuclear …, 2013 - Soc Nuclear Med
In the course of metformin treatment, staging abdominal cancer lesions with 18F-FDG PET
images is often hindered by the presence of a high bowel radioactivity. The present study …
images is often hindered by the presence of a high bowel radioactivity. The present study …
Metformin Promotes 2-Deoxy-2-[18F]Fluoro-D-Glucose Uptake in Hepatocellular Carcinoma Cells Through FoxO1-Mediated Downregulation of Glucose-6 …
Z Wang, F Kang, Y Gao, Y Liu, X Xu, X Ma… - Molecular Imaging and …, 2018 - Springer
Purpose The early diagnosis of primary hepatocellular carcinoma (HCC) has the potential to
lead to significant improvements for the treatment and survival rates of cancer patients. 2 …
lead to significant improvements for the treatment and survival rates of cancer patients. 2 …
Metformin may be associated with false-negative cancer detection in the gastrointestinal tract on PET/CT
DW Steenkamp, ME McDonnell, S Meibom - Endocrine Practice, 2014 - Elsevier
Objective Concurrent therapy with the antihyperglycemic drug metformin can hinder the
detection of malignancy in the abdominal and pelvic portions of 18 F-fluordeoxyglucose …
detection of malignancy in the abdominal and pelvic portions of 18 F-fluordeoxyglucose …
[HTML][HTML] Metformin and cancer: technical and clinical implications for FDG-PET imaging
S Capitanio, C Marini, G Sambuceti… - World journal of …, 2015 - ncbi.nlm.nih.gov
Metformin is the most widely used hypoglycemic agent. Besides its conventional indications,
increasing evidence demonstrate a potential efficacy of this biguanide as an anticancer …
increasing evidence demonstrate a potential efficacy of this biguanide as an anticancer …
Effect of metformin on 18F-fluorodeoxyglucose uptake and positron emission tomographic imaging
X Zhang, T Ogihara, M Zhu, D Gantumur… - The British journal of …, 2022 - academic.oup.com
Metformin is widely used to treat diabetes, but induces changes in glucose uptake in both
normal organs and tumors. Here, we review the effects of metformin on the uptake of 1 8F …
normal organs and tumors. Here, we review the effects of metformin on the uptake of 1 8F …
Finding the sweet spot for metformin in 18F-FDG-PET
Purpose The effect of oral hypoglycemic agents on fluorine-18-flurodeoxyglucose (18 F-
FDG) uptake is less understood than the effect of exogenous insulin. In this study, the effect …
FDG) uptake is less understood than the effect of exogenous insulin. In this study, the effect …
18F-Flortanidazole hypoxia PET holds promise as a prognostic and predictive imaging biomarker in a lung cancer xenograft model treated with metformin and …
S De Bruycker, C Vangestel… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Metformin may improve tumor oxygenation and thus radiotherapy response, but imaging
biomarkers for selection of suitable patients are still under investigation. First, we assessed …
biomarkers for selection of suitable patients are still under investigation. First, we assessed …
Differential 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models
C Cullinane, DS Dorow, S Jackson… - Journal of Nuclear …, 2011 - Soc Nuclear Med
The ability of PET to image functional changes in tumors is increasingly being used to
evaluate response and predict clinical benefit to conventional and novel cancer therapies …
evaluate response and predict clinical benefit to conventional and novel cancer therapies …